Drug Trial Radar · NCT06283589
SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Feb 12, 2024
Primary completion
Jul 27, 2024
Study completion Dec 13, 2024
Sponsor
- Lead sponsor
- Inozyme PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- BioMarin Pharmaceutical
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1, open-label, multicenter study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in adults with hemodialysis-dependent end-stage kidney disease (ESKD) and low plasma inorganic pyrophosphate (PPi) levels. Participants received INZ-701 1.8 mg/kg subcutaneously once weekly for 4 weeks. The study assessed changes in plasma PPi levels, PK characteristics, ENPP1-Fc activity, safety, tolerability, and immunogenicity.
Conditions
- Calciphylaxis
Interventions
INZ-701Drug
Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Plasma Inorganic Pyrophosphate (PPi) ConcentrationsTime frame: Baseline through Follow-up Period (up to 12 months)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
South Florida Nephrology Research
Coral Springs, Florida
Elixia Health
Hollywood, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.